Niagen Bioscience Inc. (NAGE), a commercial-stage global bioscience company that is pioneering research on NAD+ for healthy aging, reported its fourth-quarter and full-year 2025 financial results and also released its 2026 sales outlook, projecting growth of 10-15%.
For the fourth quarter, net income slipped to $4.1 million, or $0.05 per share, from $7.2 million, or $0.09 per share, in the prior-year quarter.
Total net sales for Q4, 2025, increased 16% to $33.84 million from $29.13 million a year ago.
For the full year, net income jumped to $17.38 million, or $0.20 per share, from $8.55 million, or $0.11 per share, in the prior year.
Total net sales for 2025 increased 30% to $129.4 million from $99.60 million in the prior year.
As of December 31, 2025, cash and cash equivalents totalled $64.8 million, up from $44.7 million in the prior year.
Looking ahead to 2026, net sales growth is expected to be 10-15% year-over-year, excluding 2025 revenue attributable to the Analytical Reference Standards and Services segment, driven primarily by the e-commerce business and new strategic partnerships.
The company operates through consumer products, ingredients, and pharmaceutical Segments.
Niagen is the firm's patent-protected form of nicotinamide riboside (NR), a unique form of vitamin B3. It has been clinically proven to be most efficiently converted into NAD+, the vital molecule in every living cell, according to the firm.
It provides finished dietary supplement products containing NAD+ and distributes them under the TRU NIAGEN brand to consumers.
The company also develops and commercialises proprietary ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and U.S. FDA-registered 503B outsourcing facilities, respectively.
In November 2025, the company launched Tru Niagen Beauty, a dietary supplement formulated with Niagen and other clinically studied ingredients designed to support skin, hair, and nail health.
In November 2025, the company announced results from a randomised, double-blind, placebo-controlled clinical trial evaluating Niagen supplementation in individuals with long COVID.
The study demonstrated that Niagen supplementation increased NAD+ levels, supporting continued scientific evaluation of NAD+ restoration in populations experiencing prolonged post-viral symptoms.
NAGE has traded between $4.73 and $14.69 in the last year. The stock closed Thursday's trade at $5.10, up 3.24%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.